CPhI Worldwide Announces 2017 Advisory Board

Article

CPhI Worldwide announced new additions to its 2017 advisory board.

On May 8, 2017, CPhI Worldwide announced that additional members have been added to its advisory board for the 2017 conference. The new board includes executives, consultants, and experts from the pharmaceutical industry. The advisory board will assist in shaping the agenda for the CPhI Worldwide Conference from October 24–26, 2017 in Messe Frankfurt, Germany.

The board also helps navigate improvements to the event’s co-located zones and sessions, as well identifying future opportunities and the industry’s current hot topics.

This year, the advisory board welcomes five new members:

  • Jim Miller, president of PharmSource

  • Rita Peters, editorial director of Pharmaceutical Technology, Pharmaceutical Technology Europe, and BioPharm International

  • Peter Schmitt, president of Montesino

  • Claudia Lin, general manager at AlphaMab

  • Kate Kuhrt, head of GTM Life Sciences, Clarivate Analytics.

These new members will join together with the seven current members of the expert panel Dilip G. Shah, CEO of Vision Consulting; Alan Sheppard, principal of Global Generics and Biosimilars at QuintilesIMS; Martin Folger, head of Global CMC Development-Pharmaceuticals at Boehringer Ingelheim Vetmedica GmbH; Nigel Walker, managing director of That’s Nice; Roger Bakale, vice-president of CMC and Clinical Supply Chain at Receptos; Jan Ramakers, owner of Fine Chemical Consulting Group; and Will Downie, senior vice-president of Global Sales and Marketing, Catalent Pharma Solutions.

Source: CPhI Worldwide 

Recent Videos
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Industry Outlook 2025: The Rising Prominence of AI in Pharma
Adam Sherlock, CEO of Qinecsa, discusses the changing political landscapes in the US and Europe and how that may affect the bio/pharma industry.
Adam Sherlock, CEO of Qinecsa Solutions
Related Content
© 2025 MJH Life Sciences

All rights reserved.